Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 2/20 | 0.61 |
| ▸ | NMT2 | O60551 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621551 | 0.90 | MAPT (0.53) | NMT1NMT2MAPTNPSR1GAA | |
| SCHEMBL1467161 | 0.86 | MAPK1 (0.65) | NMT1MAPTNPSR1GAAATM | |
| SCHEMBL6200293 | 0.86 | MAPK1 (0.55) | NMT1NMT2MAPTNPSR1GAA | |
| SCHEMBL538191 | 0.86 | NMT2 (0.60) | NMT1NMT2MAPTNPSR1GAA | |
| SCHEMBL22395756 | 0.86 | NMT2 (0.60) | NMT1NMT2MAPTNPSR1GAA | |
| SCHEMBL30900720 | 0.86 | NMT2 (0.60) | NMT1NMT2MAPTNPSR1GAA | |
| SCHEMBL439008 | 0.86 | NMT2 (0.60) | NMT1NMT2MAPTNPSR1GAA | |
| SCHEMBL4620616 | 0.85 | MAPT (0.51) | NMT1NMT2MAPTNPSR1GAA | |
| SCHEMBL11066821 | 0.85 | MEN1 (0.51) | NMT1NMT2MAPTNPSR1GAA | |
| SCHEMBL618410 | 0.84 | MAPT (0.62) | NMT1NMT2MAPTNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598159-B2 | Therapeutic pyrazoloquinoline derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-12-03 | — | — | US | disclosed |
| EP-2164328-B1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | DART NEUROSCIENCE CAYMAN LTD (KY) | 2013-08-07 | — | — | EP | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| US-8343957-B2 | Therapeutic pyrazoloquinoline urea derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-01-01 | — | — | US | disclosed |
| EP-2166852-B1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS INC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2166852-B1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-0172004-B1 | QUINOLINONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | The Boots Company PLC (GB) | 1990-03-21 | — | — | EP | disclosed |
| US-4855291-A | 1,4dihydroquinoline-3-carboxamides | THE BOOTS COMPANY PLC (GB) | 1989-08-08 | — | — | US | disclosed |
| US-4698350-A | 1-ethyl-6-fluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic acid and antibacterial use thereof | STERLING DRUG INC. (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0179239-A2 | 7-(Pyridinyl)-/-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid having antibacterial activity and preparation thereof | STERLING DRUG INC. (US) | 1986-04-30 | — | — | EP | disclosed |
| EP-0172004-A2 | Quinolinones, process for their preparation and pharmaceutical compositions containing them | The Boots Company PLC (GB) | 1986-02-19 | — | — | EP | disclosed |
| US-4450166-A | N-(4,5-Dihydro-thiazol-2-yl)-3-quinoline-carboxamides having anxiolytic activity | ROUSSEL UCLAF (FR) | 1984-05-22 | — | — | US | disclosed |
| US-4312870-A | TRANQUILIZERS, ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1982-01-26 | — | — | US | disclosed |
| US-4051247-A | ANTIBACTERIAL AGENTS | RIKER LABORATORIES, INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-3985753-A | ANTIBACTERIAL AGENTS | RIKER LABORATORIES, INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3976651-A | BACTERICIDE | RIKER LABORATORIES, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071140-A1 | THERAPEUTIC PYRAZOLOQUINOLINE UREA DERIVATIVES | GABRB1, GABRA5, GABRB2 | NMT1 2455/4885NMT2 2560/4885MAPT 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.